227 related articles for article (PubMed ID: 36214614)
1. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
[TBL] [Abstract][Full Text] [Related]
2. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
[TBL] [Abstract][Full Text] [Related]
3. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.
Abdelhak A; Antweiler K; Kowarik MC; Senel M; Havla J; Zettl UK; Kleiter I; Skripuletz T; Haarmann A; Stahmann A; Huss A; Gingele S; Krumbholz M; Benkert P; Kuhle J; Friede T; Ludolph AC; Ziemann U; Kümpfel T; Tumani H
Ann Clin Transl Neurol; 2024 Feb; 11(2):477-485. PubMed ID: 38111972
[TBL] [Abstract][Full Text] [Related]
4. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
5. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis.
Ammitzbøll C; Dyrby TB; Börnsen L; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Lundell H; Jensen PEH; Sørensen PS; Siebner HR; Sellebjerg F
Mult Scler Relat Disord; 2023 Sep; 77():104854. PubMed ID: 37418931
[TBL] [Abstract][Full Text] [Related]
6. Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4.
Kessler C; Ruschil C; Abdelhak A; Wilke C; Maleska A; Kuhle J; Krumbholz M; Kowarik MC; Schüle R
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362248
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: a comprehensive review and integrated analysis with glial fibrillary acidic protein.
Kim S; Lee JJ; Park JS; Kang M; Seok HY
Neurol Sci; 2024 Mar; 45(3):1255-1261. PubMed ID: 38141119
[TBL] [Abstract][Full Text] [Related]
9. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
[TBL] [Abstract][Full Text] [Related]
10. Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.
Lee HL; Seok JM; Chung YH; Min JH; Baek SH; Kim SM; Sohn E; Kim J; Kang SY; Hong YH; Shin HY; Cho JY; Oh J; Lee SS; Kim S; Kim SH; Kim HJ; Kim BJ; Kim BJ
Mult Scler Relat Disord; 2023 Nov; 79():104957. PubMed ID: 37688927
[TBL] [Abstract][Full Text] [Related]
11. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
12. Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.
Camara-Lemarroy C; Metz L; Kuhle J; Leppert D; Willemse E; Li DK; Traboulsee A; Greenfield J; Cerchiaro G; Silva C; Yong VW
Mult Scler; 2022 Nov; 28(13):2081-2089. PubMed ID: 35848622
[TBL] [Abstract][Full Text] [Related]
13. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
14. Serum glial fibrillary acidic protein and neurofilament light chain in treatment-naïve patients with unipolar depression.
Hviid CVB; Benros ME; Krogh J; Nordentoft M; Christensen SH
J Affect Disord; 2023 Oct; 338():341-348. PubMed ID: 37336248
[TBL] [Abstract][Full Text] [Related]
15. Neurofilament Light Chain and Glial Fibrillary Acidic Protein as early prognostic biomarkers after out-of-hospital cardiac arrest.
Klitholm M; Jeppesen AN; Christensen S; Parkner T; Tybirk L; Kirkegaard H; Sandfeld-Paulsen B; Grejs AM
Resuscitation; 2023 Dec; 193():109983. PubMed ID: 37778613
[TBL] [Abstract][Full Text] [Related]
16. Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
Norgren N; Sundström P; Svenningsson A; Rosengren L; Stigbrand T; Gunnarsson M
Neurology; 2004 Nov; 63(9):1586-90. PubMed ID: 15534240
[TBL] [Abstract][Full Text] [Related]
17. The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis.
Ercan Z; Bilek F; Demir CF
Mult Scler Relat Disord; 2021 Oct; 55():103219. PubMed ID: 34433118
[TBL] [Abstract][Full Text] [Related]
18. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
[TBL] [Abstract][Full Text] [Related]
19. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
Abdelhak A; Hottenrott T; Morenas-Rodríguez E; Suárez-Calvet M; Zettl UK; Haass C; Meuth SG; Rauer S; Otto M; Tumani H; Huss A
Front Neurol; 2019; 10():280. PubMed ID: 30972011
[No Abstract] [Full Text] [Related]
20. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
